Deep involvement in Japan's real estate value reshaping, focusing on metropolitan core asset M&A and restructuring, tourism-themed real estate comprehensive development, and age-friendly residential space renovation
Creating new hospitality service ecosystems, including hotel digital transformation, cultural heritage building revitalization, and medical tourism infrastructure development
Focusing on biotechnology, AI healthcare, and preventive medicine, developing home healthcare platforms for aging society
Building China-Japan goods circulation highway, empowering Japanese beauty & personal care brand expansion into China and Chinese smart manufacturing export to Japan
Biotechnology | Series A Investment
Possessing a leading domestic mRNA sequence design technology platform targeting diseases, with the latest groundbreaking rabies vaccine successfully developed and entering clinical and application stages. The first company in China to successfully complete COVID-19 vaccine animal experiments. Leading domestic mRNA vaccine R&D enterprise, with rabies vaccine in clinical stage and COVID-19 vaccine animal trials pioneering success.
Diagnostics | Series B Investment
One of China's first professional national high-tech enterprises specializing in tumor precision medicine molecular diagnostic reagent R&D and production. Independently developing and producing over 20 types of tumor precision medicine molecular diagnostic reagents, one of the most comprehensive companies in the domestic industry.
Healthcare | Series A+ Investment
A well-known preclinical CRO professional institution in East China, specializing in non-clinical drug toxicology research and safety evaluation technical services, one of the six domestic institutions with the most comprehensive non-clinical drug safety evaluation test projects.
Diagnostics | Series C Investment
A high-tech enterprise specializing in gene diagnostic product R&D, production, and sales, one of the leading domestic molecular diagnostic reagent manufacturers. The first company in China to obtain COVID-19 testing reagent medical license.
Healthcare | Series B Investment
A tumor liquid biopsy service provider with LiquidBiopsy technology and MDA test tumor liquid biopsy technology, focusing on CTC capture and detection technology research, whose products and services can assist doctors in making diagnosis and treatment recommendations for patients.
Healthcare | Series A Investment
Specializing in adolescent scoliosis correction, poor posture correction, spinal sub-health pain management, etc., adopting multi-dimensional solutions including diagnosis, assessment, exercise rehabilitation, manual correction, and physical therapy, committed to solving national spinal health problems, currently operating eight clinics in Shanghai, Hangzhou, Shenzhen, Hefei, Ningbo, and other cities.
Fintech | Strategic Investment
China's first internet bank, jointly launched by Tencent and others, serving over 370 million individual customers, world's first distributed banking core system, daily transaction peak exceeding 820 million transactions.
Fintech | Strategic Investment
China's first national-level technology platform in the credit field, serving over 800 financial institutions, independently developed "Eagle Eye" big data risk control system, covering corporate credit assessment with 98.5% accuracy, participating in formulating 30+ industry credit standards, bond market risk warning accuracy industry-leading.
Media & Culture | Strategic Investment
Satellite TV network covering 56 countries and regions, reaching 230 million users daily, exclusively operating "Oriental Culture Channel", promoting China-Japan intangible cultural heritage documentaries with global viewership exceeding 500 million.
As the Japanese legal entity of Hongyi Investment Group, we are actively deploying in the Japanese market, planning to invest in the following areas over the next three years:
We hope to become an important force in promoting China-Japan industrial collaborative development and value reconstruction through investment.
Learn About Investment Cooperation
